Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma Editorial Comment

被引：0
|
作者：
Marshall, Fray F.
机构：
来源：
JOURNAL OF UROLOGY | 2010年 / 184卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1303 / 1303
页数：1
相关论文
共 50 条
  • [31] Erratum: Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma
    A B Suttle
    H A Ball
    M Molimard
    T E Hutson
    C Carpenter
    D Rajagopalan
    Y Lin
    S Swann
    R Amado
    L Pandite
    British Journal of Cancer, 2014, 111 : 2383 - 2383
  • [32] Re: A Randomised, Double-Blind Phase III Study of Pazopanib in Patients with Advanced and/or Metastatic Renal Cell Carcinoma: Final Overall Survival Results and Safety Update Editorial Comment
    Laguna, M. Pilar
    JOURNAL OF UROLOGY, 2013, 190 (06): : 2017 - 2017
  • [33] First line pazopanib in poor risk patients with metastatic renal cell carcinoma
    Staehler, M.
    Panic, A.
    Merling, M.
    Vannier, C.
    Herrmann, E.
    Hogrefe, C.
    Potthoff, K.
    Gruenwald, V
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 203 - 203
  • [34] Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma
    Van De Sijpe, Greet
    Beuselinck, Benoit
    Van Nieuwenhuyse, Tine
    Poncelet, Roxanne
    Bechter, Oliver
    Albersen, Maarten
    Roussel, Eduard
    Baldewijns, Marcella
    Tack, Jan
    Spriet, Isabel
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 76 (09) : 1273 - 1280
  • [35] Liver toxicity in patients with metastatic renal cell carcinoma treated with pazopanib therapy
    Lim, L.
    Mathias, J.
    Lampron, M.
    Fehr, M.
    Gruenwald, V.
    Khan, M.
    Crabb, S.
    Choueiri, T.
    Powles, T.
    Rini, B.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S660 - S660
  • [36] Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma
    Greet Van De Sijpe
    Benoit Beuselinck
    Tine Van Nieuwenhuyse
    Roxanne Poncelet
    Oliver Bechter
    Maarten Albersen
    Eduard Roussel
    Marcella Baldewijns
    Jan Tack
    Isabel Spriet
    European Journal of Clinical Pharmacology, 2020, 76 : 1273 - 1280
  • [37] Effects of pazopanib (PAZ) and sunitinib (SUN) dose modification on safety and efficacy in patients with metastatic renal cell carcinoma (mRCC) from COMPARZ.
    Bjarnason, Georg A.
    Kollmannsberger, Christian K.
    Ahnnad, Qasim
    Dezzani, Luca
    Elmeliegy, Mohamed
    Han, Jackie
    Nathan, Paul D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [38] Case: Secondary polycythemia due to pazopanib in patients with metastatic renal cell carcinoma
    Bukhari, Nedal
    Winquist, Eric
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2017, 11 (11): : E449 - E450
  • [39] LIVER TOXICITY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH PAZOPANIB THERAPY
    Lim, F. L.
    Shamash, J.
    Wilson, P.
    Powles, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 290 - 290
  • [40] Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma
    LI Xue-song
    WU Xiang
    ZHAO Peng-ju
    HUANG Li-hua
    SONG Yi
    GONG Kan
    SHEN Cheng
    YU Wei
    SONG Gang
    ZHAO Zheng
    ZHANG Zheng
    ZHANG Qian
    WANG Gang
    HE Zhi-song
    ZHOU Li-qun
    JIN Jie
    中华医学杂志（英文版）, 2011, (18) : 2920 - 2924
12345